<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Venous thromboembolism risk and prevention in the severely injured trauma patient
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Venous thromboembolism risk and prevention in the severely injured trauma patient
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Venous thromboembolism risk and prevention in the severely injured trauma patient
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Elizabeth Benjamin, MD, PhD, FACS
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Eileen M Bulger, MD, FACS
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Kathryn A Collins, MD, PhD, FACS
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Geraldine Finlay, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Feb 24, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H349463666">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Risk categories for venous thromboembolism (VTE; deep vein thrombosis [DVT] or pulmonary embolism [PE]) defined by the American College of Chest Physicians  (
         <a class="graphic graphic_table graphicRef83739" href="/z/d/graphic/83739.html" rel="external">
          table 1
         </a>
         ) include moderate risk (baseline risk in the absence of prophylaxis of ≥3 percent) and high risk (ie, baseline risk in the absence of prophylaxis ≥6 percent) [
         <a href="#rid1">
          1
         </a>
         ]. A systematic review reported an overall incidence of VTE at 12 percent in trauma patients who received no prophylaxis and 7 percent in those who received only mechanical prophylaxis [
         <a href="#rid2">
          2
         </a>
         ]. However, estimates of VTE risk vary widely in this population [
         <a href="#rid3">
          3-12
         </a>
         ]. Higher rates (60 percent in one study [
         <a href="#rid3">
          3
         </a>
         ]) likely reflect patients with multiple serious injuries (eg, traumatic brain and spinal injury) or the need for multiple surgeries. Nevertheless, patients sustaining traumatic injuries are at least at moderate risk for VTE with severely injured patients at high risk for VTE [
         <a href="#rid3">
          3,13,14
         </a>
         ]. As such, thromboprophylaxis is indicated for hospitalized trauma patients. Even with appropriate prophylaxis, VTE remains a leading cause of mortality [
         <a href="#rid15">
          15
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1339.html" rel="external">
          "Prevention of venous thromboembolic disease in adult nonorthopedic surgical patients", section on 'Baseline thrombosis risk'
         </a>
         .)
        </p>
        <p>
         While pharmacologic thromboprophylaxis is desirable for decreasing the rates of DVT and PE, a clinical decision to initiate VTE prophylaxis must balance the risk of bleeding related to the patient's injuries with the risk of thrombus formation [
         <a href="#rid16">
          16
         </a>
         ].
        </p>
        <p>
         The impact of severe traumatic injury on risk, clinical evaluation, and decision-making for VTE prevention in this population is reviewed here. General considerations and recommendations are reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/1339.html" rel="external">
          "Prevention of venous thromboembolic disease in adult nonorthopedic surgical patients"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1335.html" rel="external">
          "Prevention of venous thromboembolism in adults undergoing hip fracture repair or hip or knee replacement"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2223701915">
         <span class="h1">
          PATHOPHYSIOLOGY AND RISK FACTORS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The hereditary and other acquired causes of venous thrombosis are similar to those of the general population. (See
         <a class="medical medical_review" href="/z/d/html/1361.html" rel="external">
          "Overview of the causes of venous thrombosis"
         </a>
         .)
        </p>
        <p>
         However, the occurrence of trauma introduces additional risk factors for VTE. Traumatic injury is a classic example of Virchow's triad (endothelial injury, venous stasis, hypercoagulability). But there is evidence that traumatic injury, particularly severe injury, also activates a prothrombotic state, which has been attributed to many factors, including decreased levels of functional protein C or abnormal antithrombin levels [
         <a href="#rid17">
          17,18
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2481342304">
         <span class="h2">
          Risk factors
         </span>
         <span class="headingEndMark">
          —
         </span>
         The Caprini model (
         <a class="calc calc_professional" href="/z/d/html/131707.html" rel="external">
          calculator 1
         </a>
         ), while useful for many surgical populations, has not been validated in the trauma population. Several models have sought to determine the risk factors for VTE specific to the trauma population [
         <a href="#rid3">
          3,19,20
         </a>
         ]. While knowledge of risk factors is important, prediction of events in trauma patients remains difficult. (See
         <a class="local">
          'Surveillance'
         </a>
         below.)
        </p>
        <p>
         Accepted risk factors for thromboembolism in injured patients include spinal cord injury, head trauma, lower extremity fracture, pelvic fracture, need for surgical intervention, increasing age, femoral vein line insertion, surgical repair venous injuries, prolonged immobilization, prolonged hospital stay, and high injury severity score [
         <a href="#rid3">
          3,13,21-25
         </a>
         ]. Other risk factors may also be important [
         <a href="#rid19">
          19,20,25-27
         </a>
         ]. Risk factors identified in two of the larger observational studies are presented below.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a review of 1602 VTE episodes from the National Trauma Data Bank, the following were identified as independent risk factors for VTE [
         <a href="#rid26">
          26
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Ventilator days &gt;3 (odds ratio [OR] 8.08, 95% CI 6.86-9.52)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Venous injury (OR 3.56, 95% CI 2.22-5.72)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Age ≥40 years (OR 2.01, 95% CI 1.74-2.32)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Lower extremity fracture with abbreviated injury score (AIS) ≥3 (OR 1.92, 95% CI 1.64-2.26)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Major operative procedure (OR 1.53, 95% CI 1.30-1.80)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Head injury with AIS ≥3 (OR 1.24, 95% CI 1.05-1.46)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a later review of 1233 patients, the original Greenfield risk assessment profile (RAP) score was reevaluated and simplified to include only five risk factors [
         <a href="#rid27">
          27
         </a>
         ]. Patients were separated into those with and without VTE. The groups were similar in age, sex, mechanism, and mortality, but injury severity and RAP scores were higher in those with VTE. The VTE group also had more transfusions and a longer time to VTE prophylaxis. The risks for VTE relative to no VTE for the individual factors were as follows:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         ≥4 transfusions in the first 24 hours (OR 2.60, 95% CI 1.64-4.13)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Glasgow Coma Score &lt;8 for &gt;4 hours (OR 2.13, 95% CI 1.28-3.54)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Pelvic fracture (OR 2.26, 95% CI 1.44-3.57)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         &gt;2 hour operation (OR 1.80, 95% CI 1.14-2.85)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         40 to 59 years of age (OR 1.70, 95% CI 1.10-2.63)
        </p>
        <p>
        </p>
        <p>
         There is often poor correlation between incidence of deep vein thrombosis (DVT) and pulmonary embolism (PE), with many patients presenting with PE having no evidence of extremity thrombosis [
         <a href="#rid4">
          4,20,28-30
         </a>
         ]. Whether the risk factors for DVT differ from those associated with PE in the trauma population is not well studied. Studies evaluating chest imaging (admission computed tomography scan or others early in admission) have found a fairly high incidence of PE early following traumatic injury [
         <a href="#rid31">
          31-33
         </a>
         ]. Some evidence suggests that some early PEs identified on imaging may be a result of the chest injury rather than a true thromboembolic event.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In one multicenter cohort study, differing risk factors were found for DVT versus PE among 1822 severely injured blunt trauma patients [
         <a href="#rid29">
          29,30
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For DVT, independent risk factors were delay of thromboprophylaxis &gt;48 hours after injury (OR 0.57, 95% CI 0.36-0.90) and thoracic AIS score ≥3 (OR 1.82, 95% CI 1.12-2.95).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For PE, independent risk factors were serum lactate &gt;5 (OR 2.33, 95% CI 1.43-3.79) and male sex (OR 2.12, 95% CI 1.17-3.84).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a smaller study of 110 patients with PE following injury, long bone fracture, admission to a ward (not intensive care unit), and female sex were associated with an increased risk for early PE (&lt;4 days), whereas severe head injury, severe chest injury, and major surgery within 48 hours of admission were associated with later PE.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1921605202">
         <span class="h1">
          CLINICAL FEATURES AND DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Maintaining a high level of suspicion for VTE is important when caring for trauma patients. Symptoms and signs of VTE in trauma patients are often masked by those related to the patient's injuries, which complicates detection. Extremity pain and swelling are commonly encountered. Similarly, tachycardia and desaturation events are common in trauma patients due to atelectasis, pulmonary contusion, or other injuries.
        </p>
        <p>
         When VTE is suspected, further evaluation is always warranted. The diagnosis of VTE is discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/1351.html" rel="external">
          "Clinical presentation and diagnosis of the nonpregnant adult with suspected deep vein thrombosis of the lower extremity"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8261.html" rel="external">
          "Clinical presentation, evaluation, and diagnosis of the nonpregnant adult with suspected acute pulmonary embolism"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4271553207">
         <span class="h1">
          THROMBOPROPHYLAXIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         As a population at high risk for VTE, early, aggressive thromboprophylaxis is warranted for trauma patients [
         <a href="#rid2">
          2,34
         </a>
         ]. We continue prophylaxis until hospital discharge for all high-risk patients and beyond hospital discharge for patients with significant orthopedic injuries that limit mobility. The typical strategies for preventing VTE (pharmacologic and nonpharmacologic methods) are similarly used in trauma patients. These methods are described in detail separately. It is important for the clinician to be aware that VTE prophylaxis reduces but does not eliminate the risk of VTE entirely. (See
         <a class="medical medical_review" href="/z/d/html/1339.html" rel="external">
          "Prevention of venous thromboembolic disease in adult nonorthopedic surgical patients", section on 'Administration'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4247817331">
         <span class="h2">
          Approach
         </span>
         <span class="headingEndMark">
          —
         </span>
         The optimal approach to thromboprophylaxis in patients with specific traumatic injuries remains incompletely defined [
         <a href="#rid25">
          25,35,36
         </a>
         ]. The method to use for a particular patient depends greatly upon the nature and severity of injuries  (
         <a class="graphic graphic_algorithm graphicRef130069" href="/z/d/graphic/130069.html" rel="external">
          algorithm 1
         </a>
         ) and the presence of conditions that may contraindicate their use [
         <a href="#rid2">
          2,37-43
         </a>
         ]. When possible, all hospitalized patients with traumatic injuries should receive at least one mode of prophylaxis. We generally use a combination of lower extremity mechanical compression and low-molecular-weight (LMW) heparin, depending upon the perceived risk. Patients at risk who do not have a contraindication to antithrombotic therapy should receive pharmacologic prophylaxis irrespective of their mobility. We suggest not routinely placing prophylactic inferior vena cava (IVC) filters; however, it is reasonable to use IVC filters in very-high-risk patients, particularly if there are ongoing contraindications to anticoagulation. (See
         <a class="local">
          'Prophylactic IVC filters'
         </a>
         below.)
        </p>
        <p>
         A systematic review and meta-analysis of four randomized trials of thromboprophylaxis in trauma patients found a significantly reduced risk for deep vein thrombosis (DVT) in patients receiving prophylaxis compared with no prophylaxis (4 versus 9 percent; relative risk [RR] 0.52, 95% CI 0.32-0.84) [
         <a href="#rid2">
          2
         </a>
         ]. The reduction in pulmonary embolism (PE) was not statistically significant (1.7 versus 3.3 percent; RR 0.65, 95% CI 0.29-1.43). Mortality was low in both groups (1 versus 1.4 percent; RR 0.59, 95% CI 0.2-1.70). Other findings included:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Mechanical prophylaxis reduced the risk of DVT relative to no prophylaxis (five trials; RR 0.43, 95% CI 0.25-0.73).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Pharmacological prophylaxis reduced the risk of DVT relative to mechanical prophylaxis (six trials; RR 0.48, 95% CI 0.25-0.95) but had a higher risk for minor (RR 2.37, 95% CI 1.13-4.98), but not major, bleeding.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         LMW heparin reduced the risk of DVT relative to
         <a class="drug drug_general" data-topicid="8518" href="/z/d/drug information/8518.html" rel="external">
          unfractionated heparin
         </a>
         (two trials; RR 0.68, 95% CI 0.50-0.94) with similar rates of bleeding.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Combined (mechanical and pharmacological prophylaxis) reduced the risk of DVT relative to pharmacologic prophylaxis alone (three trials; RR 0.34, 95% CI 0.19-0.60).
        </p>
        <p>
        </p>
        <p>
         The risk of VTE rises sharply if treatment is delayed beyond 72 to 96 hours [
         <a href="#rid16">
          16
         </a>
         ]. If pharmacologic prophylaxis is contraindicated for a period that will extend beyond this time frame, placement of a prophylactic IVC filter may be appropriate [
         <a href="#rid44">
          44
         </a>
         ]. (See
         <a class="local">
          'Prophylactic IVC filters'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H2116858462">
         <span class="h2">
          Antithrombotic therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         For most trauma patients, heparin (low molecular weight, unfractionated) is preferred over other antithrombotic agents (antiplatelets agents, direct oral anticoagulants). However, these are under study, and emerging data suggests they may become useful for VTE prophylaxis in the trauma population, though the specific population(s) that would most benefit has not been defined [
         <a href="#rid45">
          45-48
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2007710647">
         <span class="h3">
          Heparin
         </span>
         <span class="headingEndMark">
          —
         </span>
         For most trauma patients, LMW heparin may be superior and is preferred over
         <a class="drug drug_general" data-topicid="8518" href="/z/d/drug information/8518.html" rel="external">
          unfractionated heparin
         </a>
         (UFH) for inpatient VTE prophylaxis [
         <a href="#rid49">
          49-55
         </a>
         ]. This recommendation is consistent with guidelines from the American College of Chest Physicians (ACCP) that state a preference for LMW heparin in the trauma population [
         <a href="#rid35">
          35
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Low-dose UFH, with activity against factor Xa and thrombin, was one of the first pharmacologic agents used in the prevention of VTE and has traditionally been considered a safe and effective option in trauma patients, particularly those with high risk of bleeding, due to its reversibility. UFH is preferred in those with severe renal insufficiency (eg, creatinine clearance &lt;20 to 30 mL/min)  (
         <a class="graphic graphic_table graphicRef90258" href="/z/d/graphic/90258.html" rel="external">
          table 2
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         LMW heparin is derived from UFH and has better bioavailability and a longer half-life than UFH. Its activity is more effective against factor Xa, and it has less effect on platelets and microvascular permeability, potentially resulting in less bleeding [
         <a href="#rid56">
          56
         </a>
         ].
         <a class="drug drug_general" data-topicid="8691" href="/z/d/drug information/8691.html" rel="external">
          Fondaparinux
         </a>
         is preferred in those with heparin-induced thrombocytopenia.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         LMW heparin is more effective than the traditional twice-daily dosing of UFH for reducing VTE rates in high-risk populations [
         <a href="#rid2">
          2,49
         </a>
         ]. In a meta-analysis of two randomized trials in patients with major trauma, LMW heparin reduced the risk of DVT compared with UFH (25 versus 37 percent; RR 0.68, 95% CI 0.50-0.94) with similar rates of bleeding. Observational studies have similarly reported lower rates of DVT, lower rates of PE, and, in one study, lower mortality in patients treated with LMW heparin compared with UFH [
         <a href="#rid51">
          51,52
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3654314491">
         <span class="h4">
          Dose
         </span>
         <span class="headingEndMark">
          —
         </span>
         The optimal dosing regimen for LMW heparin in trauma patients is uncertain. Several studies have suggested that standard LMW heparin dosing, similar to UFH, has a variable effect among trauma patients and does not achieve adequate anti-Xa levels [
         <a href="#rid45">
          45,57-61
         </a>
         ]. A higher dose or twice-daily dosing may be necessary in this population, particularly if the patient is obese. Most of the studies above used standard twice-daily UFH dosing or LMW heparin in the trauma population. In one trial comparing LMW heparin with UFH given three times per day, rates of DVT were not significantly different (5.1 versus 8.2 percent; RR 0.62, 95% CI 0.3-1.28) [
         <a href="#rid62">
          62
         </a>
         ]. Adverse events were similar. In an observational study from a single institution, rates of DVT were similar before and after changing the VTE prophylaxis protocol from twice-daily LMW heparin to three times per day UFH (7 percent in both groups) [
         <a href="#rid63">
          63
         </a>
         ]. Rates of PE and bleeding were also similar.
        </p>
        <p>
         Whether there is any correlation between VTE and anti-Xa levels in trauma patients and whether monitoring anti-Xa levels to guide LMW heparin dosing is necessary is unclear. (See
         <a class="local">
          'Monitoring and adjustment'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H966849924">
         <span class="h4">
          Monitoring and adjustment
         </span>
         <span class="headingEndMark">
          —
         </span>
         Achieving adequate VTE prophylaxis remains challenging in the trauma population for a variety of reasons. For LMW heparin, monitoring anti-Xa levels has been proposed to aid dose adjustments; however, studies suggest that the efficacy of using of anti-Xa levels, like monitoring and adjustment of UFH, may be variable across subpopulations [
         <a href="#rid64">
          64-69
         </a>
         ]. In a systematic review, overall 37 percent of patients achieved prophylactic anti-Xa levels using a variety of dosing regimens [
         <a href="#rid70">
          70
         </a>
         ]. The average time to achieving prophylactic anti-Xa levels was 28 hours. While there is likely a role for anti-Xa-based monitoring and LMW heparin dose adjustment, the optimal protocol and specific trauma population that would benefit have not been determined.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a systematic review that included 45 studies of trauma or surgical patients with obesity, a variety of prophylactic (predominantly LMW heparin) dosing regimens were used, including weight-based, weight- or body mass index-stratified, and fixed-dose regimens [
         <a href="#rid65">
          65
         </a>
         ]. Target anti-Xa concentrations were more frequently achieved with weight-based or high fixed-dose regimens compared with standard fixed-dose regimens, but the incidence of DVT was similar between the groups. The high fixed-dose approach was associated with an increased risk of bleeding complications. In this study, anti-Xa levels higher than the target range were not associated with an increased incidence of bleeding, rather, most bleeding complications occurred when anti-factor Xa was within the desired range or below.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a later systematic review, three separate analyses were performed using 24 studies limited to trauma patients (excluding neurosurgery, burns and single system orthopedic injury) [
         <a href="#rid70">
          70
         </a>
         ]. Patients who received VTE prophylaxis and attained prophylactic anti-Xa levels had a reduced risk of developing VTE; however, titrating dose-adjustment strategies to achieve prophylactic anti-Xa levels paradoxically did not reduce VTE. The study authors speculated that adjustments targeting anti-Xa levels may be overly delayed to prevent VTE.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Achieving prophylactic anti-Xa levels significantly reduced the odds of experiencing a clinical VTE compared with lower levels (3.1 versus 4.0 percent; odds ratio [OR] 0.52, 95% CI 0.28–0.95).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Overall, 75 percent of patients receiving dose-adjusted
         <a class="drug drug_general" data-topicid="9407" href="/z/d/drug information/9407.html" rel="external">
          enoxaparin
         </a>
         based on anti-Xa levels achieved adequate prophylaxis (anti-Xa ≥0.2 IU/mL).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Compared with standard
         <a class="drug drug_general" data-topicid="9407" href="/z/d/drug information/9407.html" rel="external">
          enoxaparin
         </a>
         dosing, dose-adjusted enoxaparin achieved prophylactic anti-Xa levels more frequently (66 versus 45 percent; OR 4.05, 95% CI 1.80–9.03), but without a significant reduction in VTE. Patients who received dose adjustment were four times more likely to have supraprophylactic anti-Xa level, but the observed difference in bleeding was not statistically significant.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3621474669">
         <span class="h3">
          Aspirin
         </span>
         <span class="headingEndMark">
          —
         </span>
         Randomized trials have shown that
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         has the potential to change trauma practice, as it has become a reasonable alternative to LMW heparin for VTE prophylaxis in patients undergoing elective orthopedic surgery both in hospital and after discharge. However, the optimal timing (initiation) and duration of aspirin therapy remain uncertain. (See
         <a class="medical medical_review" href="/z/d/html/1335.html" rel="external">
          "Prevention of venous thromboembolism in adults undergoing hip fracture repair or hip or knee replacement", section on 'Aspirin'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/128931.html" rel="external">
          "Prevention of venous thromboembolism (VTE) in adults undergoing non-major extremity orthopedic surgery"
         </a>
         .)
        </p>
        <p>
         In an initial trial that randomly assigned 329 patients with operative extremity, pelvic, or hip fracture
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         or LMW heparin for VTE prophylaxis, aspirin was noninferior, but this study was likely underpowered [
         <a href="#rid45">
          45
         </a>
         ]. However, a subsequent, larger trial has supported these results. The PREVENTion of CLots in Orthopaedic Trauma (PREVENT CLOT) trial from the Major Extremity Trauma Research Consortium (METRC) randomized 12,211 patients with multiple trauma (mean injury severity score 9) undergoing surgical fracture fixation to aspirin (81 mg twice daily) alone or LMW heparin (
         <a class="drug drug_general" data-topicid="9407" href="/z/d/drug information/9407.html" rel="external">
          enoxaparin
         </a>
         30 mg twice daily) [
         <a href="#rid46">
          46,47
         </a>
         ]. Lower extremity fractures were treated in 87.5 percent, and lower and upper extremity fractures in 21 percent. Associated injuries were to the abdomen, spine, chest, head, and neck. The primary outcome of death occurred in 0.78 percent in the aspirin group and 0.73 percent in the LMW heparin group (96.2% CI -0.27 to 0.38; noninferiority margin). Nonfatal PE was similar for those who received aspirin alone compared with LMW heparin (PE: 1.5 percent in each group). There was a higher rate of DVT in the aspirin group (2.51 versus 1.71 percent, respectively; difference 0.8 percent, 95% CI 0.28-1.31) related to more distal DVT events. Rates of bleeding (approximately 14 percent), wound complications, and deep surgical site infection were also similar. This trial had some important limitations. Patients were allowed to receive up to two doses of LMW heparin before providing consent to participate (the numbers of doses were similar between the groups), and the duration of thromboprophylaxis in the hospital and after discharge was not mandated. In addition, the enrollment of polytrauma patients requiring mechanical ventilation in the intensive care unit was limited in this study, thus outcomes in very high-risk trauma patients remains unknown.
        </p>
        <p class="headingAnchor" id="H3550004481">
         <span class="h3">
          Direct oral anticoagulants
         </span>
         <span class="headingEndMark">
          —
         </span>
         There are data for the use of direct oral anticoagulants (DOACs) for VTE prophylaxis in a variety of postoperative populations including patients undergoing hip and knee arthroplasty. However, the use of DOACs in the trauma population is generally limited to postdischarge treatment of thromboembolic complications such as DVT/PE. Further study is needed to establish whether there is any role for the use of these agents in prophylaxis for injured patients.
        </p>
        <p class="headingAnchor" id="H2878189787">
         <span class="h2">
          Compression
         </span>
         <span class="headingEndMark">
          —
         </span>
         When the risk of bleeding is judged to be too high for anticoagulation, we suggest a mechanical method for VTE prophylaxis, principally lower extremity intermittent pneumatic compression (IPC), unless there is a specific contraindication to its use (eg, lower extremity fractures, ischemia). IPC alone is effective and is better than no prophylaxis for reducing the incidence of VTE [
         <a href="#rid2">
          2,71-73
         </a>
         ]. In a meta-analysis of five randomized trials, mechanical prophylaxis reduced the risk of DVT relative to no prophylaxis (4.5 versus 8.8 percent; RR 0.43, 95% CI 0.25-0.73) [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p>
         However, compliance with IPC is overall poor in the trauma population, underscoring the need to initiate pharmacologic prophylaxis as soon as feasible [
         <a href="#rid74">
          74-76
         </a>
         ]. Switching to or adding a pharmacologic agent, such as LMW heparin, should be done as soon as the bleeding risk becomes acceptably low (eg, 48 to 72 hours following neurosurgery) or the coagulopathy has been reversed. (See
         <a class="local">
          'Specific trauma populations'
         </a>
         below.)
        </p>
        <p>
         Concomitant mechanical prophylaxis can also be recommended for patients who are treated with pharmacologic prophylaxis. In a meta-analysis of three trials, combined mechanical and pharmacological prophylaxis reduced the risk of DVT relative to pharmacologic prophylaxis alone (RR 0.34, 95% CI 0.19-0.60) [
         <a href="#rid39">
          39
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H62912749">
         <span class="h2">
          Prophylactic IVC filters
         </span>
         <span class="headingEndMark">
          —
         </span>
         Based on large observational studies [
         <a href="#rid77">
          77-79
         </a>
         ] and one randomized trial [
         <a href="#rid80">
          80
         </a>
         ], for most severely injured trauma patients, we suggest not routinely placing prophylactic IVC filters in patients without known VTE. However, it is reasonable to use IVC filters in very-high-risk patients, particularly if there are ongoing contraindications to anticoagulation.
        </p>
        <p>
         Prophylactic IVC filters  (
         <a class="graphic graphic_figure graphicRef69737" href="/z/d/graphic/69737.html" rel="external">
          figure 1
         </a>
         ) (typically retrievable) are placed via percutaneous access into the inferior vena cava. The filter serves as a mechanical obstruction to thrombus traveling toward the pulmonary vasculature. The goal of prophylactic placement is to decrease the incidence of future PE. The possibility that prophylactic IVC filter placement may reduce PE gained early support given the high-risk nature and bleeding risks in the severely injured trauma population, particularly polytrauma patients. But while IVC filters potentially block thrombus originating in the lower half of the body from traveling proximally, they are ineffective at blocking thrombus originating from the upper extremities or neck. In addition, several complications have been described with indwelling IVC filters over time, including thrombus accumulation potentially leading to complete IVC thrombosis, filter migration, fracture, filter tilt, and vena cava perforation. (See
         <a class="medical medical_review" href="/z/d/html/8212.html" rel="external">
          "Placement of vena cava filters and their complications", section on 'Complications'
         </a>
         .)
        </p>
        <p>
         A clear consensus governing the use of prophylactic filters in trauma patients has yet to be reached. As examples, the Eastern Association for the Surgery of Trauma and Society of Interventional Radiology guidelines suggest prophylactic IVC filter use for high-risk patients with a contraindication to anticoagulation, but the ACCP guidelines do not [
         <a href="#rid1">
          1,25,81
         </a>
         ]. A later multidisciplinary guideline from an expert panel of clinicians from radiology, cardiology, pulmonology, trauma surgery and vascular surgery also suggested avoiding routine prophylactic IVC filter placement in patients without known VTE [
         <a href="#rid82">
          82
         </a>
         ]. Evidence of the efficacy and safety of prophylactic IVC filter placement in trauma patients has predominantly come from observational studies [
         <a href="#rid77">
          77,78,83-86
         </a>
         ], two small pilot studies [
         <a href="#rid87">
          87,88
         </a>
         ] and a later randomized trial [
         <a href="#rid80">
          80
         </a>
         ]. The data highlight the lack of clear survival benefit for prophylactic IVC filter placement [
         <a href="#rid77">
          77,78,80,83-85
         </a>
         ]. The incidence of PE is reduced when prophylactic IVC filters are used in patients who do not receive pharmacologic thromboprophylaxis, and while observational studies have noted an increased incidence of DVT in patients receiving IVC filters [
         <a href="#rid77">
          77,78,86,89,90
         </a>
         ], this was not confirmed in a systematic review [
         <a href="#rid83">
          83
         </a>
         ], or in the randomized trial described below [
         <a href="#rid80">
          80
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1339.html" rel="external">
          "Prevention of venous thromboembolic disease in adult nonorthopedic surgical patients", section on 'Prophylactic vena cava filters'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8212.html" rel="external">
          "Placement of vena cava filters and their complications"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a multicenter trial that included 240 patients (median Injury Severity Score [ISS] of 27), the incidence of symptomatic PE or death at 90 days was similar in patients who underwent early IVC filter placement (within 72 hours of admission) compared with controls (13.9 versus 14.4 percent, hazard ratio [HR] 0.99, 95% CI 0.51-1.94) [
         <a href="#rid80">
          80
         </a>
         ]. The use and timing of prophylactic anticoagulation and dosing were at the discretion of the clinicians. Among the subgroup of patients who survived 7 days and did not receive prophylactic anticoagulation within 7 days after injury (46 patients in the prophylactic IVC filter group, 34 patients in the control group), the incidence of symptomatic PE between day 8 and day 90 was significantly lower for patients in the IVC filter group compared with controls (0 versus 14.7 percent; HR 0, 95% CI 0.00-0.55). All the PEs occurred between day 9 and day 19 after the injury. The incidence of lower extremity DVT was similar for prophylactic IVC filter and controls (11.4 versus 10.1 percent, relative risk 1.1, 95% CI 0.6-2.3).
        </p>
        <p>
        </p>
        <p>
         Large observational studies provide further support for not routinely placing prophylactic IVC filters in trauma patients.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a study that analyzed data from a large multicenter trauma registry, hospitals were stratified into four quartiles according to the frequency of IVC filter use in trauma patients (ranging from 0.7 percent in the lowest quartile to 4.6 percent in the highest quartile) [
         <a href="#rid77">
          77
         </a>
         ]. Risk-adjusted mortality was similar in all four quartiles. In this study, rates of DVT were higher in patients who received prophylactic IVC filters compared with those who did not (5.5 versus 1.1 percent), and this association remained statistically significant after adjusting for known potential confounders such as injury severity and use of pharmacologic VTE prophylaxis (odds ratio [OR] 1.83, 95% CI 1.15-2.93).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A retrospective single-institution study of 451 trauma patients who underwent IVC filter placement and 1343 matched controls reported that among patients who survived 72 hours, hospital mortality was similar in both groups after adjusting for age, sex, and injury severity (adjusted OR 1.13, 95% CI 0.65-1.97) [
         <a href="#rid78">
          78
         </a>
         ]. Mortality rates remained similar in both groups at 6 and 12 months postinjury.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Lastly, a study analyzing data from several large clinical and administrative databases from 2003 to 2015 found that despite a precipitous decline in use of IVC filters (&gt;90 percent prophylactic) during this period, rates of PE remained essentially unchanged [
         <a href="#rid91">
          91
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Vena cava filters can be permanent or retrievable. Early studies involved treatment with permanent filters, but later studies in the trauma population reflect the growing popularity of retrievable filters, driven by the temporary nature of the post-traumatic prothrombotic state. However, the rate of filter retrieval is overall low. When a prophylactic IVC filter is placed, the trauma team should ensure that a protocol is in place to ensure that follow-up has been arranged for patients who receive a temporary IVC filter [
         <a href="#rid92">
          92
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/8212.html" rel="external">
          "Placement of vena cava filters and their complications", section on 'Filter retrieval'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1699744549">
         <span class="h1">
          SURVEILLANCE
         </span>
         <span class="headingEndMark">
          —
         </span>
         While trauma patients are at high risk for VTE, and many centers and some older trauma guidelines advocate surveillance (typically duplex ultrasound), we suggest not routinely obtaining imaging studies or other tests in an effort to identify occult deep vein thrombosis (DVT) in trauma patients [
         <a href="#rid36">
          36,93
         </a>
         ]. Surveillance incurs additional expense, and there is no conclusive evidence that outcomes are improved [
         <a href="#rid94">
          94
         </a>
         ]. However, some argue that surveillance programs increase awareness of the potential for VTE but can lead to overdiagnosis [
         <a href="#rid95">
          95-97
         </a>
         ]. In one comparative study between two hospitals with similar prophylaxis guidelines, one implemented a protocol of standard lower extremity ultrasound surveillance and the other did not [
         <a href="#rid95">
          95
         </a>
         ]. Although the rates of VTE based on clinical parameters were no different between the hospitals, the odds of receiving a diagnosis of DVT were 5.3 times higher in the hospital with the ultrasound surveillance program, suggesting a surveillance bias in centers with routine surveillance programs.
        </p>
        <p>
         Some have suggested other tests to identify trauma patients at the highest risk for VTE based upon specific risk factors [
         <a href="#rid26">
          26,98-101
         </a>
         ], including D-dimer [
         <a href="#rid102">
          102,103
         </a>
         ], or thromboelastography [
         <a href="#rid104">
          104-106
         </a>
         ]. Whether such identified patients would benefit from these methods needs to be validated in prospective studies. (See
         <a class="local">
          'Risk factors'
         </a>
         above.)
        </p>
        <p>
         As an example, one predictive model, which was created using risk factors derived from an institution with a liberal duplex protocol (intensive care unit length of stay, transfusion of blood products, spinal cord injury, pelvic fracture), was applied to the entire trauma population [
         <a href="#rid107">
          107
         </a>
         ]. The most sensitive threshold would detect only about one half of DVTs and would require testing one fourth of all trauma patients, costing nearly $600,000 to implement during the study period. The authors concluded that even using a protocol for high-risk patients would be cost prohibitive and an inappropriate utilization of resources.
        </p>
        <p class="headingAnchor" id="H1769502060">
         <span class="h1">
          SPECIFIC TRAUMA POPULATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pharmacologic thromboprophylaxis is desirable but may need to be delayed if there is any ongoing bleeding or severe coagulopathy. Data to precisely estimate the risk of bleeding in trauma patients are limited. The risk is highest in patients with major trauma, particularly with multiple serious injuries, or injuries involving the brain or spine; other injuries at risk for bleeding include solid organ injury being managed conservatively, liver injuries that have been packed, and pelvic fractures, depending upon the grade of injury and whether there is active bleeding. The approach to and timing of prophylaxis for selected injuries is reviewed in the sections below.
        </p>
        <p class="headingAnchor" id="H615100313">
         <span class="h2">
          Traumatic brain injury
         </span>
         <span class="headingEndMark">
          —
         </span>
         Given the risk associated with even minor hemorrhagic expansion of intracranial trauma, pharmacologic prophylaxis for VTE after traumatic brain injury (TBI) remains one of the most controversial topics in this field. Patients with TBI are at increased risk of VTE, likely due to such factors as hypercoagulability and prolonged immobility [
         <a href="#rid10">
          10-12,26,79
         </a>
         ]. The goal for VTE prophylaxis is to start pharmacologic therapy as soon as feasible based on bleeding risk. (See
         <a class="medical medical_review" href="/z/d/html/4826.html" rel="external">
          "Management of acute moderate and severe traumatic brain injury"
         </a>
         .)
        </p>
        <p>
         Early pharmacologic VTE prophylaxis after head trauma has received growing support in both safety and efficacy [
         <a href="#rid108">
          108-112
         </a>
         ]. Early initiation of VTE prophylaxis with low-molecular-weight (LMW) heparin within 72 hours of injury in patients with stable head computed tomography (CT) scan is supported by the American College of Surgeons Trauma Quality Improvement Program (TQIP) Best Practice Guidelines on traumatic brain injury [
         <a href="#rid113">
          113
         </a>
         ]. These guidelines refer to the modified Berne-Norwood criteria to stratify injury risk of TBI progression [
         <a href="#rid114">
          114
         </a>
         ]. The 2016 update of the Brain Trauma Foundation Guidelines also supports LMW heparin or
         <a class="drug drug_general" data-topicid="8518" href="/z/d/drug information/8518.html" rel="external">
          unfractionated heparin
         </a>
         (UFH) in combination with mechanical prophylaxis, though with no statement on timing, though acknowledging that there is an increased risk for expansion of intracranial hemorrhage [
         <a href="#rid115">
          115
         </a>
         ]. A systematic review addressed the question of timing, concluding that, based on current available literature, initiation of VTE prophylaxis within 72 hours after a stable head CT reduces VTE without a corresponding increase in intracranial hemorrhage [
         <a href="#rid116">
          116
         </a>
         ].
        </p>
        <p>
         In a retrospective study using the TQIP database that included over 3000 patients with severe TBI, early initiation of pharmacologic VTE prophylaxis within 72 hours of injury halved the rate of VTE compared with patients who received late prophylaxis (≥72 hours), without an increase in risk of death or neurosurgical intervention for new or expanding intracranial hemorrhage (ICH) [
         <a href="#rid117">
          117
         </a>
         ]. In another retrospective study in patients with ICH from TBI, the administration of early pharmacologic prophylaxis did not alter the rate of VTE or intracranial hemorrhage compared with patients treated after 48 hours [
         <a href="#rid118">
          118
         </a>
         ]. Other studies suggest similar efficacy and safety when started within 24 to 36 hours of blunt traumatic brain injury or spinal surgery [
         <a href="#rid111">
          111,119
         </a>
         ].
        </p>
        <p>
         LMW heparin may be preferable to UFH in patients with isolated TBI. In a retrospective study of 20,417 patients with isolated TBI, patients treated with LMW heparin were less likely to develop VTE compared with those treated with UFH [
         <a href="#rid120">
          120
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3940698767">
         <span class="h2">
          Spinal cord injury
         </span>
         <span class="headingEndMark">
          —
         </span>
         Deep vein thrombosis (DVT) is a common complication of traumatic spinal cord injury, occurring in 50 to 100 percent of untreated patients, with the greatest incidence between 72 hours and 14 days. The increased risk for VTE continues into the rehabilitation phase [
         <a href="#rid7">
          7-9
         </a>
         ]. Based upon observational data, most recommend consideration of early initiation of pharmacologic prophylaxis using LMW heparin within 72 hours after spinal cord injury [
         <a href="#rid36">
          36,121-124
         </a>
         ].
        </p>
        <p>
         Patients with traumatic spinal cord injury, especially those with new-onset paraplegia or quadriplegia, are a subset of the trauma population considered very high risk for VTE [
         <a href="#rid3">
          3,22,125,126
         </a>
         ]. The level and severity of injury does not clearly have an impact on the risk for DVT [
         <a href="#rid127">
          127,128
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4819.html" rel="external">
          "Acute traumatic spinal cord injury", section on 'Venous thromboembolism and pulmonary embolism'
         </a>
         .)
        </p>
        <p>
         Early initiation of VTE prophylaxis is widely regarded as a treatment priority [
         <a href="#rid129">
          129
         </a>
         ], and, although there is significant variability among practitioners, this population is considered by some to be an indication for prophylactic inferior vena cava (IVC) filter placement, particularly in those patients who are not candidates for anticoagulation [
         <a href="#rid25">
          25,90,121,130
         </a>
         ]. Whether use of prophylactic IVC filters contributes to increased DVT risk in spinal cord injured patients is uncertain. Studies have reported increased rates of DVT in patients with prophylactic IVC filters compared with those without filters (20 versus 5 percent, in one study) [
         <a href="#rid90">
          90
         </a>
         ]. However, given the retrospective nature of these data, it is possible that the observed differences may have been due in part to selection bias and/or other confounding factors (eg, pharmacologic VTE prophylaxis usage). (See
         <a class="local">
          'Prophylactic IVC filters'
         </a>
         above.)
        </p>
        <p>
         Early initiation of pharmacologic VTE prophylaxis, at less than 72 hours, is associated with a reduced incidence of DVT in patients with spinal cord injury [
         <a href="#rid126">
          126,131
         </a>
         ]. This desire for early prophylaxis, however, is tempered by concern for expansion of intraspinal hematoma. However, in a single-center retrospective study of 501 patients with spinal cord injury, expansion of intraspinal hematoma occurred rarely (1 percent) with similar rates seen in patients who received early pharmacologic prophylaxis compared with those who did not [
         <a href="#rid131">
          131
         </a>
         ]. In a retrospective cohort study of 1432 patients with spinal fractures, 14 percent of whom had operative fixation, early pharmacologic VTE prophylaxis initiated within 24 hours was not associated with an increased risk of postoperative bleeding or epidural hematoma [
         <a href="#rid132">
          132
         </a>
         ].
        </p>
        <p>
         LMW heparin may be preferred in patients with spinal cord injury. In a small randomized trial comparing LMW heparin with UFH three times daily in 41 patients with spinal cord injury, overall VTE rates and bleeding complications were similar [
         <a href="#rid133">
          133
         </a>
         ]. However, patients who received LMW heparin had a lower incidence of pulmonary embolism (PE). In another trial, 107 patients were randomized to
         <a class="drug drug_general" data-topicid="9407" href="/z/d/drug information/9407.html" rel="external">
          enoxaparin
         </a>
         or UFH in combination with intermittent pneumatic compression [
         <a href="#rid134">
          134
         </a>
         ]. Rates of DVT were similar (65.6 versus 63.3 percent). However, the incidence of PE was lower for enoxaparin (5.2 versus 18.4 percent), as was the incidence of major bleeding (2.6 versus 5.3 percent).
        </p>
        <p class="headingAnchor" id="H3531050472">
         <span class="h2">
          Pelvis or extremity injury
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with pelvic fracture or severe extremity injury (ie, multiple fracture, fracture associated with nerve or vascular injury), particularly lower extremity injuries, are at high risk for VTE. Patients should receive mechanical and pharmacologic prophylaxis for VTE as soon as is feasible [
         <a href="#rid16">
          16
         </a>
         ]. Pelvic fractures also increase the risk for VTE, and early prophylaxis is associated with lower rates of VTE and improved mortality [
         <a href="#rid135">
          135
         </a>
         ] VTE prophylaxis for less severe or isolated extremity injury is reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/128931.html" rel="external">
          "Prevention of venous thromboembolism (VTE) in adults undergoing non-major extremity orthopedic surgery"
         </a>
         .)
        </p>
        <p>
         The most important risk factors are likely related directly to the pelvic and extremity injury and immobilization. Venous repair does not appear to increase the incidence of venous thromboembolic complications based on a review of 103 venous injuries [
         <a href="#rid136">
          136
         </a>
         ]. In this study, DVT occurred at 10 sites remote from the vascular injury site in 82 total patients. There were three vein thromboses in 34 repairs. In a review of 237 venous injuries, only a delay in starting thromboprophylaxis independently predicted VTE after controlling for injury severity score, hemodynamics, injured vessel, and surgical subspecialty [
         <a href="#rid137">
          137
         </a>
         ].
        </p>
        <p>
         With rare exception, anticoagulation should be continued perioperatively during subsequent procedures given the high risk of thromboembolic complications in this population. (See
         <a class="medical medical_review" href="/z/d/html/16732.html" rel="external">
          "Surgical management of severe lower extremity injury"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2503073796">
         <span class="h2">
          Solid organ injury
         </span>
         <span class="headingEndMark">
          —
         </span>
         As with all trauma patients, early pharmacologic prophylaxis is considered a goal in management even among those with solid organ injury, but due to the potential hemorrhagic complications of anticoagulation, many practitioners are hesitant to initiate early pharmacologic prophylaxis after solid organ injury. Despite the growing body of evidence to support early VTE prophylaxis after solid organ injury, definitive recommendations are awaiting prospective evaluation. Based on observational studies showing that thromboprophylaxis does not increase the rate of bleeding or failure of nonoperative management in patients with solid organ injury [
         <a href="#rid42">
          42,138-143
         </a>
         ], we suggest early initiation of VTE prophylaxis within 48 hours, typically initiating treatment when the hemoglobin has stabilized with minimal change over a 24 hour period of time [
         <a href="#rid144">
          144
         </a>
         ]. However, pharmacologic prophylaxis may be contraindicated by associated injuries. (See
         <a class="medical medical_review" href="/z/d/html/7957.html" rel="external">
          "Management of splenic injury in the adult trauma patient"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/15143.html" rel="external">
          "Management of hepatic trauma in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/16214.html" rel="external">
          "Management of blunt and penetrating renal trauma"
         </a>
         .)
        </p>
        <p>
         Most of the literature has focused on the safety of VTE prophylaxis, especially in the setting of nonoperative management. Small retrospective studies have suggested that early thromboprophylaxis (within 48 hours) may be safe following splenic trauma, but there are currently no standards for the initiation of prophylaxis in patients who are managed nonoperatively [
         <a href="#rid42">
          42,140,145
         </a>
         ]. In a retrospective review of 162 patients with blunt solid organ injury (spleen, liver, kidney), initiation of pharmacologic prophylaxis within 48 hours was safe and was not associated with an increased need for operative management for bleeding [
         <a href="#rid145">
          145
         </a>
         ]. Similarly, in a retrospective case-matched series of patients with blunt splenic injury treated nonoperatively, early initiation of VTE within 48 hours of injury was not associated with increased need for additional interventions [
         <a href="#rid140">
          140
         </a>
         ]. In a single-center study from Alabama in the United States that included 328 patients, early VTE prophylaxis was associated with fewer VTE complications, and there were no hemorrhagic complications associated with its use [
         <a href="#rid42">
          42
         </a>
         ]. These results were similar to an earlier study for which there was no significant difference in the rate of failure of nonoperative management or the volume of transfusion required for early compared with later prophylaxis [
         <a href="#rid146">
          146
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3221996185">
         <span class="h2">
          Pediatric trauma considerations
         </span>
         <span class="headingEndMark">
          —
         </span>
         In contrast to the adult population, pediatric trauma patients (age &lt;14) have a lower incidence of VTE, ranging from 0.3 to 1.2 percent [
         <a href="#rid147">
          147-150
         </a>
         ]. Thus, the risk:benefit ratio for pharmacologic prophylaxis is less favorable in this population, and it may not be appropriate to apply guidelines used in adult trauma patients. Major risk factors for VTE include the presence of a central venous catheter [CVC], adolescent (postpubertal) age, increasing injury severity, and operative intervention [
         <a href="#rid147">
          147-150
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5918.html" rel="external">
          "Venous thrombosis and thromboembolism (VTE) in children: Risk factors, clinical manifestations, and diagnosis", section on 'Risk of VTE in children versus adults'
         </a>
         .)
        </p>
        <p>
         Our approach to VTE prophylaxis in children is based primarily on the age of the child [
         <a href="#rid151">
          151,152
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Prepubertal children (age &lt;15 years) – Based on the available data, we suggest
         <strong>
          not
         </strong>
         routinely initiating pharmacologic VTE prophylaxis in prepubertal trauma patients. However, pharmacologic prophylaxis may be appropriate if there are
         <strong>
          multiple
         </strong>
         additional risk factors that place the child at particularly high risk for VTE (eg, high severity of injury, critical illness, major surgery, transfusion, need for mechanical ventilation, previous history of VTE, severe obesity, prolonged immobility, CVC). (See
         <a class="medical medical_review" href="/z/d/html/5916.html" rel="external">
          "Venous thrombosis and thromboembolism (VTE) in children: Treatment, prevention, and outcome", section on 'Approach to VTE prophylaxis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Postpubertal adolescents (age ≥15 years) – The risk of VTE in postpubertal adolescent patients with major trauma approaches that in adult populations [
         <a href="#rid149">
          149,150
         </a>
         ]. Thus, we suggest using the adult recommendations outlined above in this age group.
        </p>
        <p>
        </p>
        <p>
         Our approach is generally consistent with the guidelines of the Eastern Association for the Surgery of Trauma and the Pediatric Trauma Society [
         <a href="#rid151">
          151,152
         </a>
         ].
        </p>
        <p>
         Pediatric VTE risk prediction models and decision algorithms have been developed, though none have been prospectively validated [
         <a href="#rid153">
          153-156
         </a>
         ]. Factors included in these risk prediction models vary slightly based on the specific model. Most models include age, Glasgow Coma Score, injury severity score, sex, major surgery, transfusion, and critical illness (eg, intensive care unit admission or need for intubation or inotropic agent); some also include sex, presence of a CVC, immobilization, and pelvic or lower extremity fracture [
         <a href="#rid153">
          153,154,156
         </a>
         ]. The models all appear to accurately identify patients at increased risk for VTE (ie, among patients with the highest predicted risk, actual rates of VTE range from 5 to 10 percent).
        </p>
        <p class="headingAnchor" id="H27927591">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/113663.html" rel="external">
          "Society guideline links: Superficial vein thrombosis, deep vein thrombosis, and pulmonary embolism"
         </a>
         and
         <a class="medical medical_society_guidelines" href="/z/d/html/118154.html" rel="external">
          "Society guideline links: General issues of trauma management in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3751610133">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Venous thromboembolism risk
         </strong>
         – Patients with trauma are,
         <strong>
          at a minimum
         </strong>
         , at moderate risk for venous thromboembolism (VTE; deep vein thrombosis [DVT], pulmonary embolism [PE]). Severely injured patients are at high risk for VTE. In addition to typical risk factors for VTE, factors that increase the risk for VTE in trauma patients include spinal cord injury, head trauma, lower extremity fracture, pelvic fracture, and high injury severity score. (See
         <a class="local">
          'Introduction'
         </a>
         above and
         <a class="local">
          'Risk factors'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical surveillance
         </strong>
         – For trauma patients, associated injuries can mask presenting symptoms/signs of VTE and complicate their detection. A high level of suspicion is needed, and further evaluation is warranted whenever VTE is suspected. For most trauma patients, we do not suggest routine imaging surveillance to identify occult VTE. Many centers do routinely image trauma patients, but there is no conclusive evidence that outcomes are improved. (See
         <a class="local">
          'Clinical features and diagnosis'
         </a>
         above and
         <a class="local">
          'Surveillance'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          VTE prophylaxis
         </strong>
         – As a population at risk for VTE, severely injured patients should receive early, aggressive VTE prophylaxis. We continue prophylaxis until hospital discharge for all high-risk patients and beyond hospital discharge with patients with significant orthopedic injuries that limit mobility. It is important for the clinician to be aware that VTE prophylaxis reduces but does not eliminate the risk of VTE entirely. Even with appropriate prophylaxis, VTE remains a leading cause of mortality in hospitalized trauma patients. Our approach to VTE prophylaxis in adult trauma patients with severe injury is provided below. The recommendations for pharmacologic prophylaxis are also appropriate for high-risk postpuberty pediatric trauma patients.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Low bleeding risk
         </strong>
         – For patients with a low risk for bleeding, we recommend combined pharmacologic and mechanical thromboprophylaxis rather than mechanical prophylaxis alone (
         <a class="grade" href="https:///uptodate/show/grade_2" rel="external">
          Grade 1B
         </a>
         ), and further suggest combined thromboprophylaxis rather than pharmacologic prophylaxis alone (
         <a class="grade" href="https:///uptodate/show/grade_5" rel="external">
          Grade 2B
         </a>
         ). Combined pharmacologic and mechanical thromboprophylaxis is more effective than either modality alone. (See
         <a class="local">
          'Thromboprophylaxis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          High risk for bleeding
         </strong>
         – For patients with bleeding risk deemed too high to permit pharmacologic thromboprophylaxis, we suggest mechanical methods, rather than no prophylaxis (
         <a class="grade" href="https:///uptodate/show/grade_5" rel="external">
          Grade 2B
         </a>
         ). This typically consists of intermittent pneumatic compression (IPC) provided there are no contraindications (eg, external fixation, extremity ischemia). IPC alone is more effective than no prophylaxis for preventing DVT and can generally be applied to at least one extremity. Pharmacologic prophylaxis should be started as soon as the bleeding risk has resolved. (See
         <a class="local">
          'Compression'
         </a>
         above and
         <a class="local">
          'Specific trauma populations'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Antithrombotic agent and dose
         </strong>
         – When pharmacologic prophylaxis is used, we suggest low-molecular-weight (LMW) heparin rather than
         <a class="drug drug_general" data-topicid="8518" href="/z/d/drug information/8518.html" rel="external">
          unfractionated heparin
         </a>
         (UFH) for most patients (
         <a class="grade" href="https:///uptodate/show/grade_5" rel="external">
          Grade 2B
         </a>
         ). UFH is preferred in those with severe renal insufficiency (eg, creatinine clearance &lt;30 mL/min). For most patients, we suggest initiating pharmacologic thromboprophylaxis within 72 hours rather than initiating it later (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). The nature of the specific injuries dictates where in the provided time range is more appropriate. (See
         <a class="local">
          'Antithrombotic therapy'
         </a>
         above and
         <a class="local">
          'Specific trauma populations'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Role of vena cava filters
         </strong>
         – For most severely injured trauma patients, we suggest not placing prophylactic inferior vena cava (IVC) filters (
         <a class="grade" href="https:///uptodate/show/grade_5" rel="external">
          Grade 2B
         </a>
         ). Most patients can be started on pharmacologic thromboprophylaxis reasonably early in the postinjury period, and early placement of an IVC filter does not appear to be beneficial in such patients. However, it is reasonable to use IVC filters in very-high-risk patients, particularly if there are ongoing contraindications to anticoagulation. When retrievable IVC filters are used, a protocol for follow-up should be used to ensure that the filter is removed in a timely fashion. (See
         <a class="local">
          'Prophylactic IVC filters'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/8212.html" rel="external">
          "Placement of vena cava filters and their complications", section on 'Filter retrieval'
         </a>
         .)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Gould MK, Garcia DA, Wren SM, et al. Prevention of VTE in nonorthopedic surgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e227S.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barrera LM, Perel P, Ker K, et al. Thromboprophylaxis for trauma patients. Cochrane Database Syst Rev 2013; :CD008303.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Geerts WH, Code KI, Jay RM, et al. A prospective study of venous thromboembolism after major trauma. N Engl J Med 1994; 331:1601.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cipolle MD, Wojcik R, Seislove E, et al. The role of surveillance duplex scanning in preventing venous thromboembolism in trauma patients. J Trauma 2002; 52:453.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hemmila MR, Jakubus JL, Maggio PM, et al. Real money: complications and hospital costs in trauma patients. Surgery 2008; 144:307.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Platzer P, Thalhammer G, Jaindl M, et al. Thromboembolic complications after spinal surgery in trauma patients. Acta Orthop 2006; 77:755.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jones T, Ugalde V, Franks P, et al. Venous thromboembolism after spinal cord injury: incidence, time course, and associated risk factors in 16,240 adults and children. Arch Phys Med Rehabil 2005; 86:2240.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chen D, Apple DF Jr, Hudson LM, Bode R. Medical complications during acute rehabilitation following spinal cord injury--current experience of the Model Systems. Arch Phys Med Rehabil 1999; 80:1397.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Green D, Hartwig D, Chen D, et al. Spinal Cord Injury Risk Assessment for Thromboembolism (SPIRATE Study). Am J Phys Med Rehabil 2003; 82:950.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Denson K, Morgan D, Cunningham R, et al. Incidence of venous thromboembolism in patients with traumatic brain injury. Am J Surg 2007; 193:380.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim KS, Brophy GM. Symptomatic venous thromboembolism: incidence and risk factors in patients with spontaneous or traumatic intracranial hemorrhage. Neurocrit Care 2009; 11:28.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reiff DA, Haricharan RN, Bullington NM, et al. Traumatic brain injury is associated with the development of deep vein thrombosis independent of pharmacological prophylaxis. J Trauma 2009; 66:1436.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meissner MH, Chandler WL, Elliott JS. Venous thromboembolism in trauma: a local manifestation of systemic hypercoagulability? J Trauma 2003; 54:224.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Azarbal A, Rowell S, Lewis J, et al. Duplex ultrasound screening detects high rates of deep vein thromboses in critically ill trauma patients. J Vasc Surg 2011; 54:743.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           O'Donnell M, Weitz JI. Thromboprophylaxis in surgical patients. Can J Surg 2003; 46:129.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nathens AB, McMurray MK, Cuschieri J, et al. The practice of venous thromboembolism prophylaxis in the major trauma patient. J Trauma 2007; 62:557.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Engelman DT, Gabram SG, Allen L, et al. Hypercoagulability following multiple trauma. World J Surg 1996; 20:5.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Owings JT, Bagley M, Gosselin R, et al. Effect of critical injury on plasma antithrombin activity: low antithrombin levels are associated with thromboembolic complications. J Trauma 1996; 41:396.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Selby R, Geerts W, Ofosu FA, et al. Hypercoagulability after trauma: hemostatic changes and relationship to venous thromboembolism. Thromb Res 2009; 124:281.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shuster R, Mathew J, Olaussen A, et al. Variables associated with pulmonary thromboembolism in injured patients: A systematic review. Injury 2018; 49:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Spain DA, Richardson JD, Polk HC Jr, et al. Venous thromboembolism in the high-risk trauma patient: do risks justify aggressive screening and prophylaxis? J Trauma 1997; 42:463.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Velmahos GC, Kern J, Chan LS, et al. Prevention of venous thromboembolism after injury: an evidence-based report--part I: analysis of risk factors and evaluation of the role of vena caval filters. J Trauma 2000; 49:132.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Malinoski D, Ewing T, Patel MS, et al. Risk factors for venous thromboembolism in critically ill trauma patients who cannot receive chemical prophylaxis. Injury 2013; 44:80.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Coleman JJ, Zarzaur BL, Katona CW, et al. Factors associated with pulmonary embolism within 72 hours of admission after trauma: a multicenter study. J Am Coll Surg 2015; 220:731.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rogers FB, Cipolle MD, Velmahos G, et al. Practice management guidelines for the prevention of venous thromboembolism in trauma patients: the EAST practice management guidelines work group. J Trauma 2002; 53:142.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Knudson MM, Ikossi DG, Khaw L, et al. Thromboembolism after trauma: an analysis of 1602 episodes from the American College of Surgeons National Trauma Data Bank. Ann Surg 2004; 240:490.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meizoso JP, Karcutskie CA 4th, Ray JJ, et al. A simplified stratification system for venous thromboembolism risk in severely injured trauma patients. J Surg Res 2017; 207:138.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tadlock MD, Chouliaras K, Kennedy M, et al. The origin of fatal pulmonary emboli: a postmortem analysis of 500 deaths from pulmonary embolism in trauma, surgical, and medical patients. Am J Surg 2015; 209:959.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brakenridge SC, Henley SS, Kashner TM, et al. Comparing clinical predictors of deep venous thrombosis versus pulmonary embolus after severe injury: a new paradigm for posttraumatic venous thromboembolism? J Trauma Acute Care Surg 2013; 74:1231.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brakenridge SC, Toomay SM, Sheng JL, et al. Predictors of early versus late timing of pulmonary embolus after traumatic injury. Am J Surg 2011; 201:209.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Spencer Netto F, Tien H, Ng J, et al. Pulmonary emboli after blunt trauma: timing, clinical characteristics and natural history. Injury 2012; 43:1502.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gelbard RB, Karamanos E, Farhoomand A, et al. Immediate post-traumatic pulmonary embolism is not associated with right ventricular dysfunction. Am J Surg 2016; 212:769.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Menaker J, Stein DM, Scalea TM. Incidence of early pulmonary embolism after injury. J Trauma 2007; 63:620.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rogers F, Rebuck JA, Sing RF. Venous thromboembolism in trauma: an update for the intensive care unit practitioner. J Intensive Care Med 2007; 22:26.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hirsh J, Raschke R. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126:188S.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133:381S.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ley EJ, Brown CVR, Moore EE, et al. Updated guidelines to reduce venous thromboembolism in trauma patients: A Western Trauma Association critical decisions algorithm. J Trauma Acute Care Surg 2020; 89:971.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bandle J, Shackford SR, Sise CB, et al. Variability is the standard: the management of venous thromboembolic disease following trauma. J Trauma Acute Care Surg 2014; 76:213.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kakkos SK, Caprini JA, Geroulakos G, et al. Combined intermittent pneumatic leg compression and pharmacological prophylaxis for prevention of venous thromboembolism in high-risk patients. Cochrane Database Syst Rev 2008; :CD005258.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kwiatt ME, Patel MS, Ross SE, et al. Is low-molecular-weight heparin safe for venous thromboembolism prophylaxis in patients with traumatic brain injury? A Western Trauma Association multicenter study. J Trauma Acute Care Surg 2012; 73:625.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saadeh Y, Gohil K, Bill C, et al. Chemical venous thromboembolic prophylaxis is safe and effective for patients with traumatic brain injury when started 24 hours after the absence of hemorrhage progression on head CT. J Trauma Acute Care Surg 2012; 73:426.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rostas JW, Manley J, Gonzalez RP, et al. The safety of low molecular-weight heparin after blunt liver and spleen injuries. Am J Surg 2015; 210:31.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kurtoglu M, Yanar H, Bilsel Y, et al. Venous thromboembolism prophylaxis after head and spinal trauma: intermittent pneumatic compression devices versus low molecular weight heparin. World J Surg 2004; 28:807.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Decousus H, Leizorovicz A, Parent F, et al. A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Prévention du Risque d'Embolie Pulmonaire par Interruption Cave Study Group. N Engl J Med 1998; 338:409.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Haac BE, O'Hara NN, Manson TT, et al. Aspirin versus low-molecular-weight heparin for venous thromboembolism prophylaxis in orthopaedic trauma patients: A patient-centered randomized controlled trial. PLoS One 2020; 15:e0235628.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Major Extremity Trauma Research Consortium (METRC), O'Toole RV, Stein DM, et al. Aspirin or Low-Molecular-Weight Heparin for Thromboprophylaxis after a Fracture. N Engl J Med 2023; 388:203.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           O'Toole RV, Stein DM, Frey KP, et al. PREVENTion of CLots in Orthopaedic Trauma (PREVENT CLOT): a randomised pragmatic trial protocol comparing aspirin versus low-molecular-weight heparin for blood clot prevention in orthopaedic trauma patients. BMJ Open 2021; 11:e041845.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brill JB, Calvo RY, Wallace JD, et al. Aspirin as added prophylaxis for deep vein thrombosis in trauma: A retrospective case-control study. J Trauma Acute Care Surg 2016; 80:625.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Geerts WH, Jay RM, Code KI, et al. A comparison of low-dose heparin with low-molecular-weight heparin as prophylaxis against venous thromboembolism after major trauma. N Engl J Med 1996; 335:701.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bush S, LeClaire A, Hampp C, Lottenberg L. Review of a large clinical series: once- versus twice-daily enoxaparin for venous thromboembolism prophylaxis in high-risk trauma patients. J Intensive Care Med 2011; 26:111.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jacobs BN, Cain-Nielsen AH, Jakubus JL, et al. Unfractionated heparin versus low-molecular-weight heparin for venous thromboembolism prophylaxis in trauma. J Trauma Acute Care Surg 2017; 83:151.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Byrne JP, Geerts W, Mason SA, et al. Effectiveness of low-molecular-weight heparin versus unfractionated heparin to prevent pulmonary embolism following major trauma: A propensity-matched analysis. J Trauma Acute Care Surg 2017; 82:252.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e419S.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Holbrook A, Schulman S, Witt DM, et al. Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e152S.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Geerts WH, Pineo GF, Heit JA, et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126:338S.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weitz JI. Low-molecular-weight heparins. N Engl J Med 1997; 337:688.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Anderson DR, Dunbar M, Murnaghan J, et al. Aspirin or Rivaroxaban for VTE Prophylaxis after Hip or Knee Arthroplasty. N Engl J Med 2018; 378:699.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sun G, Wu J, Wang Q, et al. Factor Xa Inhibitors and Direct Thrombin Inhibitors Versus Low-Molecular-Weight Heparin for Thromboprophylaxis After Total Hip or Total Knee Arthroplasty: A Systematic Review and Meta-Analysis. J Arthroplasty 2019; 34:789.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ghosh A, Best AJ, Rudge SJ, Chatterji U. Clinical Effectiveness of Aspirin as Multimodal Thromboprophylaxis in Primary Total Hip and Knee Arthroplasty: A Review of 6078 Cases. J Arthroplasty 2019; 34:1359.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marcucci M, Etxeandia-Ikobaltzeta I, Yang S, et al. Benefits and harms of direct oral anticoagulation and low molecular weight heparin for thromboprophylaxis in patients undergoing non-cardiac surgery: systematic review and network meta-analysis of randomised trials. BMJ 2022; 376:e066785.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Samama CM, Laporte S, Rosencher N, et al. Rivaroxaban or Enoxaparin in Nonmajor Orthopedic Surgery. N Engl J Med 2020; 382:1916.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Olson EJ, Bandle J, Calvo RY, et al. Heparin versus enoxaparin for prevention of venous thromboembolism after trauma: A randomized noninferiority trial. J Trauma Acute Care Surg 2015; 79:961.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arnold JD, Dart BW, Barker DE, et al. Gold Medal Forum Winner. Unfractionated heparin three times a day versus enoxaparin in the prevention of deep vein thrombosis in trauma patients. Am Surg 2010; 76:563.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Imran JB, Madni TD, Clark AT, et al. Inability to predict subprophylactic anti-factor Xa levels in trauma patients receiving early low-molecular-weight heparin. J Trauma Acute Care Surg 2018; 85:867.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shaikh S, Boneva D, Hai S, et al. Venous thromboembolism chemoprophylaxis regimens in trauma and surgery patients with obesity: A systematic review. J Trauma Acute Care Surg 2020; 88:522.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Walker CK, Sandmann EA, Horyna TJ, Gales MA. Increased Enoxaparin Dosing for Venous Thromboembolism Prophylaxis in General Trauma Patients. Ann Pharmacother 2017; 51:323.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ko A, Harada MY, Barmparas G, et al. Association Between Enoxaparin Dosage Adjusted by Anti-Factor Xa Trough Level and Clinically Evident Venous Thromboembolism After Trauma. JAMA Surg 2016; 151:1006.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kopelman TR, O'Neill PJ, Pieri PG, et al. Alternative dosing of prophylactic enoxaparin in the trauma patient: is more the answer? Am J Surg 2013; 206:911.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berndtson AE, Costantini TW, Lane J, et al. If some is good, more is better: An enoxaparin dosing strategy to improve pharmacologic venous thromboembolism prophylaxis. J Trauma Acute Care Surg 2016; 81:1095.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Verhoeff K, Raffael K, Connell M, et al. Relationship between anti-Xa level achieved with prophylactic low-molecular weight heparin and venous thromboembolism in trauma patients: A systematic review and meta-analysis. J Trauma Acute Care Surg 2022; 93:e61.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Knudson MM, Lewis FR, Clinton A, et al. Prevention of venous thromboembolism in trauma patients. J Trauma 1994; 37:480.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fisher CG, Blachut PA, Salvian AJ, et al. Effectiveness of pneumatic leg compression devices for the prevention of thromboembolic disease in orthopaedic trauma patients: a prospective, randomized study of compression alone versus no prophylaxis. J Orthop Trauma 1995; 9:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ginzburg E, Cohn SM, Lopez J, et al. Randomized clinical trial of intermittent pneumatic compression and low molecular weight heparin in trauma. Br J Surg 2003; 90:1338.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cornwell EE 3rd, Chang D, Velmahos G, et al. Compliance with sequential compression device prophylaxis in at-risk trauma patients: a prospective analysis. Am Surg 2002; 68:470.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Comerota AJ, Katz ML, White JV. Why does prophylaxis with external pneumatic compression for deep vein thrombosis fail? Am J Surg 1992; 164:265.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Murakami M, McDill TL, Cindrick-Pounds L, et al. Deep venous thrombosis prophylaxis in trauma: improved compliance with a novel miniaturized pneumatic compression device. J Vasc Surg 2003; 38:923.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hemmila MR, Osborne NH, Henke PK, et al. Prophylactic Inferior Vena Cava Filter Placement Does Not Result in a Survival Benefit for Trauma Patients. Ann Surg 2015; 262:577.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sarosiek S, Rybin D, Weinberg J, et al. Association Between Inferior Vena Cava Filter Insertion in Trauma Patients and In-Hospital and Overall Mortality. JAMA Surg 2017; 152:75.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Van Gent JM, Bandle J, Calvo RY, et al. Isolated traumatic brain injury and venous thromboembolism. J Trauma Acute Care Surg 2014; 77:238.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ho KM, Rao S, Honeybul S, et al. A Multicenter Trial of Vena Cava Filters in Severely Injured Patients. N Engl J Med 2019; 381:328.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaufman JA, Kinney TB, Streiff MB, et al. Guidelines for the use of retrievable and convertible vena cava filters: report from the Society of Interventional Radiology multidisciplinary consensus conference. J Vasc Interv Radiol 2006; 17:449.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaufman JA, Barnes GD, Chaer RA, et al. Society of Interventional Radiology Clinical Practice Guideline for Inferior Vena Cava Filters in the Treatment of Patients with Venous Thromboembolic Disease: Developed in collaboration with the American College of Cardiology, American College of Chest Physicians, American College of Surgeons Committee on Trauma, American Heart Association, Society for Vascular Surgery, and Society for Vascular Medicine. J Vasc Interv Radiol 2020; 31:1529.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Haut ER, Garcia LJ, Shihab HM, et al. The effectiveness of prophylactic inferior vena cava filters in trauma patients: a systematic review and meta-analysis. JAMA Surg 2014; 149:194.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mismetti P, Laporte S, Pellerin O, et al. Effect of a retrievable inferior vena cava filter plus anticoagulation vs anticoagulation alone on risk of recurrent pulmonary embolism: a randomized clinical trial. JAMA 2015; 313:1627.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kidane B, Madani AM, Vogt K, et al. The use of prophylactic inferior vena cava filters in trauma patients: a systematic review. Injury 2012; 43:542.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Girard TD, Philbrick JT, Fritz Angle J, Becker DM. Prophylactic vena cava filters for trauma patients: a systematic review of the literature. Thromb Res 2003; 112:261.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rajasekhar A, Lottenberg L, Lottenberg R, et al. A pilot study on the randomization of inferior vena cava filter placement for venous thromboembolism prophylaxis in high-risk trauma patients. J Trauma 2011; 71:323.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ho KM, Rao S, Honeybul S, et al. Detailed assessment of benefits and risks of retrievable inferior vena cava filters on patients with complicated injuries: the da Vinci multicentre randomised controlled trial study protocol. BMJ Open 2017; 7:e016747.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rajasekhar A, Lottenberg R, Lottenberg L, et al. Pulmonary embolism prophylaxis with inferior vena cava filters in trauma patients: a systematic review using the meta-analysis of observational studies in epidemiology (MOOSE) guidelines. J Thromb Thrombolysis 2011; 32:40.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gorman PH, Qadri SF, Rao-Patel A. Prophylactic inferior vena cava (IVC) filter placement may increase the relative risk of deep venous thrombosis after acute spinal cord injury. J Trauma 2009; 66:707.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cook AD, Gross BW, Osler TM, et al. Vena Cava Filter Use in Trauma and Rates of Pulmonary Embolism, 2003-2015. JAMA Surg 2017; 152:724.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smoot RL, Koch CA, Heller SF, et al. Inferior vena cava filters in trauma patients: efficacy, morbidity, and retrievability. J Trauma 2010; 68:899.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Falck-Ytter Y, Francis CW, Johanson NA, et al. Prevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e278S.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meyer CS, Blebea J, Davis K Jr, et al. Surveillance venous scans for deep venous thrombosis in multiple trauma patients. Ann Vasc Surg 1995; 9:109.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shackford SR, Cipolle MD, Badiee J, et al. Determining the magnitude of surveillance bias in the assessment of lower extremity deep venous thrombosis: A prospective observational study of two centers. J Trauma Acute Care Surg 2016; 80:734.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Haut ER, Chang DC, Pierce CA, et al. Predictors of posttraumatic deep vein thrombosis (DVT): hospital practice versus patient factors-an analysis of the National Trauma Data Bank (NTDB). J Trauma 2009; 66:994.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dietch ZC, Edwards BL, Thames M, et al. Rate of lower-extremity ultrasonography in trauma patients is associated with rate of deep venous thrombosis but not pulmonary embolism. Surgery 2015; 158:379.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Greenfield LJ, Proctor MC, Rodriguez JL, et al. Posttrauma thromboembolism prophylaxis. J Trauma 1997; 42:100.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ho KM, Rao S, Rittenhouse KJ, Rogers FB. Use of the Trauma Embolic Scoring System (TESS) to predict symptomatic deep vein thrombosis and fatal and non-fatal pulmonary embolism in severely injured patients. Anaesth Intensive Care 2014; 42:709.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rogers FB, Shackford SR, Horst MA, et al. Determining venous thromboembolic risk assessment for patients with trauma: the Trauma Embolic Scoring System. J Trauma Acute Care Surg 2012; 73:511.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zander AL, Van Gent JM, Olson EJ, et al. Venous thromboembolic risk assessment models should not solely guide prophylaxis and surveillance in trauma patients. J Trauma Acute Care Surg 2015; 79:194.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yumoto T, Naito H, Yamakawa Y, et al. Venous thromboembolism in major trauma patients: a single-center retrospective cohort study of the epidemiology and utility of D-dimer for screening. Acute Med Surg 2017; 4:394.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ahuja RB, Bansal P, Pradhan GS, Subberwal M. An analysis of deep vein thrombosis in burn patients (Part 1): Comparison of D-dimer and Doppler ultrasound as screening tools. Burns 2016; 42:1686.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Holcomb JB, Minei KM, Scerbo ML, et al. Admission rapid thrombelastography can replace conventional coagulation tests in the emergency department: experience with 1974 consecutive trauma patients. Ann Surg 2012; 256:476.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brill JB, Badiee J, Zander AL, et al. The rate of deep vein thrombosis doubles in trauma patients with hypercoagulable thromboelastography. J Trauma Acute Care Surg 2017; 83:413.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Park MS, Spears GM, Bailey KR, et al. Thrombin generation profiles as predictors of symptomatic venous thromboembolism after trauma: A prospective cohort study. J Trauma Acute Care Surg 2017; 83:381.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dietch ZC, Petroze RT, Thames M, et al. The "high-risk" deep venous thrombosis screening protocol for trauma patients: Is it practical? J Trauma Acute Care Surg 2015; 79:970.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jamjoom AA, Jamjoom AB. Safety and efficacy of early pharmacological thromboprophylaxis in traumatic brain injury: systematic review and meta-analysis. J Neurotrauma 2013; 30:503.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Farooqui A, Hiser B, Barnes SL, Litofsky NS. Safety and efficacy of early thromboembolism chemoprophylaxis after intracranial hemorrhage from traumatic brain injury. J Neurosurg 2013; 119:1576.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Phelan HA, Wolf SE, Norwood SH, et al. A randomized, double-blinded, placebo-controlled pilot trial of anticoagulation in low-risk traumatic brain injury: The Delayed Versus Early Enoxaparin Prophylaxis I (DEEP I) study. J Trauma Acute Care Surg 2012; 73:1434.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Norwood SH, Berne JD, Rowe SA, et al. Early venous thromboembolism prophylaxis with enoxaparin in patients with blunt traumatic brain injury. J Trauma 2008; 65:1021.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Koehler DM, Shipman J, Davidson MA, Guillamondegui O. Is early venous thromboembolism prophylaxis safe in trauma patients with intracranial hemorrhage. J Trauma 2011; 70:324.
          </a>
         </li>
         <li class="breakAll">
          https://www.facs.org/~/media/files/quality%20programs/trauma/tqip/traumatic%20brain%20injury%20guidelines.ashx (Accessed on October 13, 2017).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pastorek RA, Cripps MW, Bernstein IH, et al. The Parkland Protocol's modified Berne-Norwood criteria predict two tiers of risk for traumatic brain injury progression. J Neurotrauma 2014; 31:1737.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brain Trauma Foundation, American Association of Neurological Surgeons, Congress of Neurological Surgeons, et al. Guidelines for the management of severe traumatic brain injury. V. Deep vein thrombosis prophylaxis. J Neurotrauma 2007; 24 Suppl 1:S32.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Spano PJ 2nd, Shaikh S, Boneva D, et al. Anticoagulant chemoprophylaxis in patients with traumatic brain injuries: A systematic review. J Trauma Acute Care Surg 2020; 88:454.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Byrne JP, Mason SA, Gomez D, et al. Timing of Pharmacologic Venous Thromboembolism Prophylaxis in Severe Traumatic Brain Injury: A Propensity-Matched Cohort Study. J Am Coll Surg 2016; 223:621.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Frisoli F, Huang PP, Frangos S. 180 Early Deep Vein Thrombosis Chemoprophylaxis in Traumatic Brain Injury. Neurosurgery 2016; 63 Suppl 1:171.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Strom RG, Frempong-Boadu AK. Low-molecular-weight heparin prophylaxis 24 to 36 hours after degenerative spine surgery: risk of hemorrhage and venous thromboembolism. Spine (Phila Pa 1976) 2013; 38:E1498.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Benjamin E, Recinos G, Aiolfi A, et al. Pharmacological Thromboembolic Prophylaxis in Traumatic Brain Injuries: Low Molecular Weight Heparin Is Superior to Unfractionated Heparin. Ann Surg 2017; 266:463.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dhall SS, Hadley MN, Aarabi B, et al. Deep venous thrombosis and thromboembolism in patients with cervical spinal cord injuries. Neurosurgery 2013; 72 Suppl 2:244.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Christie S, Thibault-Halman G, Casha S. Acute pharmacological DVT prophylaxis after spinal cord injury. J Neurotrauma 2011; 28:1509.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Teasell RW, Hsieh JT, Aubut JA, et al. Venous thromboembolism after spinal cord injury. Arch Phys Med Rehabil 2009; 90:232.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Van PY, Schreiber MA. Contemporary thromboprophylaxis of trauma patients. Curr Opin Crit Care 2016; 22:607.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fujii Y, Mammen EF, Farag A, et al. Thrombosis in spinal cord injury. Thromb Res 1992; 68:357.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aito S, Pieri A, D'Andrea M, et al. Primary prevention of deep venous thrombosis and pulmonary embolism in acute spinal cord injured patients. Spinal Cord 2002; 40:300.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Velmahos GC, Kern J, Chan LS, et al. Prevention of venous thromboembolism after injury: an evidence-based report--part II: analysis of risk factors and evaluation of the role of vena caval filters. J Trauma 2000; 49:140.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Merli GJ, Crabbe S, Paluzzi RG, Fritz D. Etiology, incidence, and prevention of deep vein thrombosis in acute spinal cord injury. Arch Phys Med Rehabil 1993; 74:1199.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Powell M, Kirshblum S, O'Connor KC. Duplex ultrasound screening for deep vein thrombosis in spinal cord injured patients at rehabilitation admission. Arch Phys Med Rehabil 1999; 80:1044.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ozturk C, Ganiyusufoglu K, Alanay A, et al. Efficacy of prophylactic placement of inferior vena cava filter in patients undergoing spinal surgery. Spine (Phila Pa 1976) 2010; 35:1893.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chang R, Scerbo MH, Schmitt KM, et al. Early chemoprophylaxis is associated with decreased venous thromboembolism risk without concomitant increase in intraspinal hematoma expansion after traumatic spinal cord injury. J Trauma Acute Care Surg 2017; 83:1088.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim DY, Kobayashi L, Chang D, et al. Early pharmacological venous thromboembolism prophylaxis is safe after operative fixation of traumatic spine fractures. Spine (Phila Pa 1976) 2015; 40:299.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Green D, Lee MY, Lim AC, et al. Prevention of thromboembolism after spinal cord injury using low-molecular-weight heparin. Ann Intern Med 1990; 113:571.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Spinal Cord Injury Thromboprophylaxis Investigators. Prevention of venous thromboembolism in the acute treatment phase after spinal cord injury: a randomized, multicenter trial comparing low-dose heparin plus intermittent pneumatic compression with enoxaparin. J Trauma 2003; 54:1116.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Benjamin E, Aiolfi A, Recinos G, et al. Timing of venous thromboprophylaxis in isolated severe pelvic fracture: Effect on mortality and outcomes. Injury 2019; 50:697.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Quan RW, Gillespie DL, Stuart RP, et al. The effect of vein repair on the risk of venous thromboembolic events: a review of more than 100 traumatic military venous injuries. J Vasc Surg 2008; 47:571.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Frank B, Maher Z, Hazelton JP, et al. Venous thromboembolism after major venous injuries: Competing priorities. J Trauma Acute Care Surg 2017; 83:1095.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Datta I, Ball CG, Rudmik LR, et al. A multicenter review of deep venous thrombosis prophylaxis practice patterns for blunt hepatic trauma. J Trauma Manag Outcomes 2009; 3:7.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eberle BM, Schnüriger B, Inaba K, et al. Thromboembolic prophylaxis with low-molecular-weight heparin in patients with blunt solid abdominal organ injuries undergoing nonoperative management: current practice and outcomes. J Trauma 2011; 70:141.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kwok AM, Davis JW, Dirks RC, et al. Time is now: venous thromboembolism prophylaxis in blunt splenic injury. Am J Surg 2016; 212:1231.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Norwood SH, McAuley CE, Berne JD, et al. A potentially expanded role for enoxaparin in preventing venous thromboembolism in high risk blunt trauma patients. J Am Coll Surg 2001; 192:161.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Khatsilouskaya T, Haltmeier T, Cathomas M, et al. Thromboembolic Prophylaxis with Heparin in Patients with Blunt Solid Organ Injuries Undergoing Non-operative Treatment. World J Surg 2017; 41:1193.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Joseph B, Pandit V, Harrison C, et al. Early thromboembolic prophylaxis in patients with blunt solid abdominal organ injuries undergoing nonoperative management: is it safe? Am J Surg 2015; 209:194.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schellenberg M, Inaba K, Biswas S, et al. When is It Safe to Start VTE Prophylaxis After Blunt Solid Organ Injury? A Prospective Study from a Level I Trauma Center. World J Surg 2019; 43:2797.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Murphy PB, Sothilingam N, Charyk Stewart T, et al. Very early initiation of chemical venous thromboembolism prophylaxis after blunt solid organ injury is safe. Can J Surg 2016; 59:118.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alejandro KV, Acosta JA, Rodríguez PA. Bleeding manifestations after early use of low-molecular-weight heparins in blunt splenic injuries. Am Surg 2003; 69:1006.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cyr C, Michon B, Pettersen G, et al. Venous thromboembolism after severe injury in children. Acta Haematol 2006; 115:198.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vavilala MS, Nathens AB, Jurkovich GJ, et al. Risk factors for venous thromboembolism in pediatric trauma. J Trauma 2002; 52:922.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Allen CJ, Murray CR, Meizoso JP, et al. Risk factors for venous thromboembolism after pediatric trauma. J Pediatr Surg 2016; 51:168.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Azu MC, McCormack JE, Scriven RJ, et al. Venous thromboembolic events in pediatric trauma patients: is prophylaxis necessary? J Trauma 2005; 59:1345.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mahajerin A, Petty JK, Hanson SJ, et al. Prophylaxis against venous thromboembolism in pediatric trauma: A practice management guideline from the Eastern Association for the Surgery of Trauma and the Pediatric Trauma Society. J Trauma Acute Care Surg 2017; 82:627.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hanson SJ, Faustino EV, Mahajerin A, et al. Recommendations for venous thromboembolism prophylaxis in pediatric trauma patients: A national, multidisciplinary consensus study. J Trauma Acute Care Surg 2016; 80:695.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yen J, Van Arendonk KJ, Streiff MB, et al. Risk Factors for Venous Thromboembolism in Pediatric Trauma Patients and Validation of a Novel Scoring System: The Risk of Clots in Kids With Trauma Score. Pediatr Crit Care Med 2016; 17:391.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Connelly CR, Laird A, Barton JS, et al. A Clinical Tool for the Prediction of Venous Thromboembolism in Pediatric Trauma Patients. JAMA Surg 2016; 151:50.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hanson SJ, Punzalan RC, Greenup RA, et al. Incidence and risk factors for venous thromboembolism in critically ill children after trauma. J Trauma 2010; 68:52.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Landisch RM, Hanson SJ, Cassidy LD, et al. Evaluation of guidelines for injured children at high risk for venous thromboembolism: A prospective observational study. J Trauma Acute Care Surg 2017; 82:836.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 113028 Version 16.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22315263" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Prevention of VTE in nonorthopedic surgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23543562" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Thromboprophylaxis for trauma patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7969340" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : A prospective study of venous thromboembolism after major trauma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11901319" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : The role of surveillance duplex scanning in preventing venous thromboembolism in trauma patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18656640" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Real money: complications and hospital costs in trauma patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17068706" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Thromboembolic complications after spinal surgery in trauma patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16344018" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Venous thromboembolism after spinal cord injury: incidence, time course, and associated risk factors in 16,240 adults and children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10569433" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Medical complications during acute rehabilitation following spinal cord injury--current experience of the Model Systems.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14627932" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Spinal Cord Injury Risk Assessment for Thromboembolism (SPIRATE Study).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17320539" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Incidence of venous thromboembolism in patients with traumatic brain injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19238588" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Symptomatic venous thromboembolism: incidence and risk factors in patients with spontaneous or traumatic intracranial hemorrhage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19430251" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Traumatic brain injury is associated with the development of deep vein thrombosis independent of pharmacological prophylaxis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12579044" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Venous thromboembolism in trauma: a local manifestation of systemic hypercoagulability?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21620614" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Duplex ultrasound screening detects high rates of deep vein thromboses in critically ill trauma patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12691354" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Thromboprophylaxis in surgical patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17414328" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : The practice of venous thromboembolism prophylaxis in the major trauma patient.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8588412" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Hypercoagulability following multiple trauma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8810955" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Effect of critical injury on plasma antithrombin activity: low antithrombin levels are associated with thromboembolic complications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19041119" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Hypercoagulability after trauma: hemostatic changes and relationship to venous thromboembolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28843717" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Variables associated with pulmonary thromboembolism in injured patients: A systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9095114" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Venous thromboembolism in the high-risk trauma patient: do risks justify aggressive screening and prophylaxis?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10912869" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Prevention of venous thromboembolism after injury: an evidence-based report--part I: analysis of risk factors and evaluation of the role of vena caval filters.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22047757" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Risk factors for venous thromboembolism in critically ill trauma patients who cannot receive chemical prophylaxis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25724603" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Factors associated with pulmonary embolism within 72 hours of admission after trauma: a multicenter study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12131409" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Practice management guidelines for the prevention of venous thromboembolism in trauma patients: the EAST practice management guidelines work group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15319720" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Thromboembolism after trauma: an analysis of 1602 episodes from the American College of Surgeons National Trauma Data Bank.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27979470" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : A simplified stratification system for venous thromboembolism risk in severely injured trauma patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25669120" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : The origin of fatal pulmonary emboli: a postmortem analysis of 500 deaths from pulmonary embolism in trauma, surgical, and medical patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23609272" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Comparing clinical predictors of deep venous thrombosis versus pulmonary embolus after severe injury: a new paradigm for posttraumatic venous thromboembolism?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20385370" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Predictors of early versus late timing of pulmonary embolus after traumatic injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21722897" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Pulmonary emboli after blunt trauma: timing, clinical characteristics and natural history.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26545343" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Immediate post-traumatic pulmonary embolism is not associated with right ventricular dysfunction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18073610" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Incidence of early pulmonary embolism after injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17259566" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Venous thromboembolism in trauma: an update for the intensive care unit practitioner.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15383472" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18574271" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32590563" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Updated guidelines to reduce venous thromboembolism in trauma patients: A Western Trauma Association critical decisions algorithm.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24368382" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Variability is the standard: the management of venous thromboembolic disease following trauma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18843686" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Combined intermittent pneumatic leg compression and pharmacological prophylaxis for prevention of venous thromboembolism in high-risk patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22929493" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Is low-molecular-weight heparin safe for venous thromboembolism prophylaxis in patients with traumatic brain injury? A Western Trauma Association multicenter study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22846950" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Chemical venous thromboembolic prophylaxis is safe and effective for patients with traumatic brain injury when started 24 hours after the absence of hemorrhage progression on head CT.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25510476" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : The safety of low molecular-weight heparin after blunt liver and spleen injuries.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15457363" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Venous thromboembolism prophylaxis after head and spinal trauma: intermittent pneumatic compression devices versus low molecular weight heparin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9459643" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Prévention du Risque d'Embolie Pulmonaire par Interruption Cave Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32745092" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Aspirin versus low-molecular-weight heparin for venous thromboembolism prophylaxis in orthopaedic trauma patients: A patient-centered randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36652352" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Aspirin or Low-Molecular-Weight Heparin for Thromboprophylaxis after a Fracture.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33762229" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : PREVENTion of CLots in Orthopaedic Trauma (PREVENT CLOT): a randomised pragmatic trial protocol comparing aspirin versus low-molecular-weight heparin for blood clot prevention in orthopaedic trauma patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26808030" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Aspirin as added prophylaxis for deep vein thrombosis in trauma: A retrospective case-control study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8703169" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : A comparison of low-dose heparin with low-molecular-weight heparin as prophylaxis against venous thromboembolism after major trauma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21257630" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Review of a large clinical series: once- versus twice-daily enoxaparin for venous thromboembolism prophylaxis in high-risk trauma patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28426561" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Unfractionated heparin versus low-molecular-weight heparin for venous thromboembolism prophylaxis in trauma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27906870" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Effectiveness of low-molecular-weight heparin versus unfractionated heparin to prevent pulmonary embolism following major trauma: A propensity-matched analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22315268" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22315259" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15383478" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9278467" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Low-molecular-weight heparins.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29466159" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Aspirin or Rivaroxaban for VTE Prophylaxis after Hip or Knee Arthroplasty.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30685261" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Factor Xa Inhibitors and Direct Thrombin Inhibitors Versus Low-Molecular-Weight Heparin for Thromboprophylaxis After Total Hip or Total Knee Arthroplasty: A Systematic Review and Meta-Analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30982759" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Clinical Effectiveness of Aspirin as Multimodal Thromboprophylaxis in Primary Total Hip and Knee Arthroplasty: A Review of 6078 Cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35264372" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Benefits and harms of direct oral anticoagulation and low molecular weight heparin for thromboprophylaxis in patients undergoing non-cardiac surgery: systematic review and network meta-analysis of randomised trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32223113" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Rivaroxaban or Enoxaparin in Nonmajor Orthopedic Surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26317819" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Heparin versus enoxaparin for prevention of venous thromboembolism after trauma: A randomized noninferiority trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20583509" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Gold Medal Forum Winner. Unfractionated heparin three times a day versus enoxaparin in the prevention of deep vein thrombosis in trauma patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29985229" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Inability to predict subprophylactic anti-factor Xa levels in trauma patients receiving early low-molecular-weight heparin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31688792" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Venous thromboembolism chemoprophylaxis regimens in trauma and surgery patients with obesity: A systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28228055" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Increased Enoxaparin Dosing for Venous Thromboembolism Prophylaxis in General Trauma Patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27383732" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Association Between Enoxaparin Dosage Adjusted by Anti-Factor Xa Trough Level and Clinically Evident Venous Thromboembolism After Trauma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24296098" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Alternative dosing of prophylactic enoxaparin in the trauma patient: is more the answer?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27244575" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : If some is good, more is better: An enoxaparin dosing strategy to improve pharmacologic venous thromboembolism prophylaxis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35195094" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Relationship between anti-Xa level achieved with prophylactic low-molecular weight heparin and venous thromboembolism in trauma patients: A systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8083913" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Prevention of venous thromboembolism in trauma patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7714648" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Effectiveness of pneumatic leg compression devices for the prevention of thromboembolic disease in orthopaedic trauma patients: a prospective, randomized study of compression alone versus no prophylaxis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14598411" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Randomized clinical trial of intermittent pneumatic compression and low molecular weight heparin in trauma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12017149" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Compliance with sequential compression device prophylaxis in at-risk trauma patients: a prospective analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1415927" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Why does prophylaxis with external pneumatic compression for deep vein thrombosis fail?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14603195" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Deep venous thrombosis prophylaxis in trauma: improved compliance with a novel miniaturized pneumatic compression device.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26366537" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Prophylactic Inferior Vena Cava Filter Placement Does Not Result in a Survival Benefit for Trauma Patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27682367" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Association Between Inferior Vena Cava Filter Insertion in Trauma Patients and In-Hospital and Overall Mortality.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25058248" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Isolated traumatic brain injury and venous thromboembolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31259488" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : A Multicenter Trial of Vena Cava Filters in Severely Injured Patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16567669" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Guidelines for the use of retrievable and convertible vena cava filters: report from the Society of Interventional Radiology multidisciplinary consensus conference.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32919823" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Society of Interventional Radiology Clinical Practice Guideline for Inferior Vena Cava Filters in the Treatment of Patients with Venous Thromboembolic Disease: Developed in collaboration with the American College of Cardiology, American College of Chest Physicians, American College of Surgeons Committee on Trauma, American Heart Association, Society for Vascular Surgery, and Society for Vascular Medicine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24195920" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : The effectiveness of prophylactic inferior vena cava filters in trauma patients: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25919526" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Effect of a retrievable inferior vena cava filter plus anticoagulation vs anticoagulation alone on risk of recurrent pulmonary embolism: a randomized clinical trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22386925" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : The use of prophylactic inferior vena cava filters in trauma patients: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15041267" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Prophylactic vena cava filters for trauma patients: a systematic review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21825934" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : A pilot study on the randomization of inferior vena cava filter placement for venous thromboembolism prophylaxis in high-risk trauma patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28706106" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Detailed assessment of benefits and risks of retrievable inferior vena cava filters on patients with complicated injuries: the da Vinci multicentre randomised controlled trial study protocol.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21221716" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Pulmonary embolism prophylaxis with inferior vena cava filters in trauma patients: a systematic review using the meta-analysis of observational studies in epidemiology (MOOSE) guidelines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19276742" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Prophylactic inferior vena cava (IVC) filter placement may increase the relative risk of deep venous thrombosis after acute spinal cord injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28492861" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Vena Cava Filter Use in Trauma and Rates of Pulmonary Embolism, 2003-2015.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20386285" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Inferior vena cava filters in trauma patients: efficacy, morbidity, and retrievability.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22315265" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Prevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7703054" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Surveillance venous scans for deep venous thrombosis in multiple trauma patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26891155" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Determining the magnitude of surveillance bias in the assessment of lower extremity deep venous thrombosis: A prospective observational study of two centers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19359905" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Predictors of posttraumatic deep vein thrombosis (DVT): hospital practice versus patient factors-an analysis of the National Trauma Data Bank (NTDB).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26032827" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Rate of lower-extremity ultrasonography in trauma patients is associated with rate of deep venous thrombosis but not pulmonary embolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9003265" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Posttrauma thromboembolism prophylaxis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25342402" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Use of the Trauma Embolic Scoring System (TESS) to predict symptomatic deep vein thrombosis and fatal and non-fatal pulmonary embolism in severely injured patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23019680" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Determining venous thromboembolic risk assessment for patients with trauma: the Trauma Embolic Scoring System.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26218685" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : Venous thromboembolic risk assessment models should not solely guide prophylaxis and surveillance in trauma patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29123899" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : Venous thromboembolism in major trauma patients: a single-center retrospective cohort study of the epidemiology and utility of D-dimer for screening.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27639819" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : An analysis of deep vein thrombosis in burn patients (Part 1): Comparison of D-dimer and Doppler ultrasound as screening tools.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22868371" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : Admission rapid thrombelastography can replace conventional coagulation tests in the emergency department: experience with 1974 consecutive trauma patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28598908" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : The rate of deep vein thrombosis doubles in trauma patients with hypercoagulable thromboelastography.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28362683" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : Thrombin generation profiles as predictors of symptomatic venous thromboembolism after trauma: A prospective cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26488317" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : The "high-risk" deep venous thrombosis screening protocol for trauma patients: Is it practical?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23517138" id="rid107" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          108 : Safety and efficacy of early pharmacological thromboprophylaxis in traumatic brain injury: systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24053504" id="rid108" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          109 : Safety and efficacy of early thromboembolism chemoprophylaxis after intracranial hemorrhage from traumatic brain injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22914079" id="rid109" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          110 : A randomized, double-blinded, placebo-controlled pilot trial of anticoagulation in low-risk traumatic brain injury: The Delayed Versus Early Enoxaparin Prophylaxis I (DEEP I) study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19001969" id="rid110" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          111 : Early venous thromboembolism prophylaxis with enoxaparin in patients with blunt traumatic brain injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21307729" id="rid111" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          112 : Is early venous thromboembolism prophylaxis safe in trauma patients with intracranial hemorrhage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21307729" id="rid112" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          113 : Is early venous thromboembolism prophylaxis safe in trauma patients with intracranial hemorrhage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24945196" id="rid113" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          114 : The Parkland Protocol's modified Berne-Norwood criteria predict two tiers of risk for traumatic brain injury progression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17511543" id="rid114" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          115 : Guidelines for the management of severe traumatic brain injury. V. Deep vein thrombosis prophylaxis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31923051" id="rid115" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          116 : Anticoagulant chemoprophylaxis in patients with traumatic brain injuries: A systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27453296" id="rid116" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          117 : Timing of Pharmacologic Venous Thromboembolism Prophylaxis in Severe Traumatic Brain Injury: A Propensity-Matched Cohort Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27399459" id="rid117" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          118 : 180 Early Deep Vein Thrombosis Chemoprophylaxis in Traumatic Brain Injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23873245" id="rid118" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          119 : Low-molecular-weight heparin prophylaxis 24 to 36 hours after degenerative spine surgery: risk of hemorrhage and venous thromboembolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28650361" id="rid119" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          120 : Pharmacological Thromboembolic Prophylaxis in Traumatic Brain Injuries: Low Molecular Weight Heparin Is Superior to Unfractionated Heparin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23417195" id="rid120" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          121 : Deep venous thrombosis and thromboembolism in patients with cervical spinal cord injuries.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20795870" id="rid121" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          122 : Acute pharmacological DVT prophylaxis after spinal cord injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19236977" id="rid122" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          123 : Venous thromboembolism after spinal cord injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27749357" id="rid123" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          124 : Contemporary thromboprophylaxis of trauma patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1290164" id="rid124" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          125 : Thrombosis in spinal cord injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12037712" id="rid125" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          126 : Primary prevention of deep venous thrombosis and pulmonary embolism in acute spinal cord injured patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10912870" id="rid126" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          127 : Prevention of venous thromboembolism after injury: an evidence-based report--part II: analysis of risk factors and evaluation of the role of vena caval filters.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8239962" id="rid127" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          128 : Etiology, incidence, and prevention of deep vein thrombosis in acute spinal cord injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10489006" id="rid128" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          129 : Duplex ultrasound screening for deep vein thrombosis in spinal cord injured patients at rehabilitation admission.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20802386" id="rid129" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          130 : Efficacy of prophylactic placement of inferior vena cava filter in patients undergoing spinal surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28863085" id="rid130" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          131 : Early chemoprophylaxis is associated with decreased venous thromboembolism risk without concomitant increase in intraspinal hematoma expansion after traumatic spinal cord injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25901977" id="rid131" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          132 : Early pharmacological venous thromboembolism prophylaxis is safe after operative fixation of traumatic spine fractures.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2169216" id="rid132" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          133 : Prevention of thromboembolism after spinal cord injury using low-molecular-weight heparin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12813332" id="rid133" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          134 : Prevention of venous thromboembolism in the acute treatment phase after spinal cord injury: a randomized, multicenter trial comparing low-dose heparin plus intermittent pneumatic compression with enoxaparin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30797543" id="rid134" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          135 : Timing of venous thromboprophylaxis in isolated severe pelvic fracture: Effect on mortality and outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18295108" id="rid135" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          136 : The effect of vein repair on the risk of venous thromboembolic events: a review of more than 100 traumatic military venous injuries.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28700413" id="rid136" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          137 : Venous thromboembolism after major venous injuries: Competing priorities.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19493337" id="rid137" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          138 : A multicenter review of deep venous thrombosis prophylaxis practice patterns for blunt hepatic trauma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21217492" id="rid138" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          139 : Thromboembolic prophylaxis with low-molecular-weight heparin in patients with blunt solid abdominal organ injuries undergoing nonoperative management: current practice and outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27810135" id="rid139" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          140 : Time is now: venous thromboembolism prophylaxis in blunt splenic injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11220715" id="rid140" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          141 : A potentially expanded role for enoxaparin in preventing venous thromboembolism in high risk blunt trauma patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27942848" id="rid141" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          142 : Thromboembolic Prophylaxis with Heparin in Patients with Blunt Solid Organ Injuries Undergoing Non-operative Treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24928334" id="rid142" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          143 : Early thromboembolic prophylaxis in patients with blunt solid abdominal organ injuries undergoing nonoperative management: is it safe?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31367780" id="rid143" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          144 : When is It Safe to Start VTE Prophylaxis After Blunt Solid Organ Injury? A Prospective Study from a Level I Trauma Center.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26820318" id="rid144" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          145 : Very early initiation of chemical venous thromboembolism prophylaxis after blunt solid organ injury is safe.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14627266" id="rid145" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          146 : Bleeding manifestations after early use of low-molecular-weight heparins in blunt splenic injuries.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16549896" id="rid146" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          147 : Venous thromboembolism after severe injury in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11988660" id="rid147" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          148 : Risk factors for venous thromboembolism in pediatric trauma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26547285" id="rid148" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          149 : Risk factors for venous thromboembolism after pediatric trauma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16394907" id="rid149" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          150 : Venous thromboembolic events in pediatric trauma patients: is prophylaxis necessary?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28030503" id="rid150" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          151 : Prophylaxis against venous thromboembolism in pediatric trauma: A practice management guideline from the Eastern Association for the Surgery of Trauma and the Pediatric Trauma Society.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26881487" id="rid151" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          152 : Recommendations for venous thromboembolism prophylaxis in pediatric trauma patients: A national, multidisciplinary consensus study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26963757" id="rid152" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          153 : Risk Factors for Venous Thromboembolism in Pediatric Trauma Patients and Validation of a Novel Scoring System: The Risk of Clots in Kids With Trauma Score.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26422678" id="rid153" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          154 : A Clinical Tool for the Prediction of Venous Thromboembolism in Pediatric Trauma Patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20065757" id="rid154" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          155 : Incidence and risk factors for venous thromboembolism in critically ill children after trauma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28430759" id="rid155" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          156 : Evaluation of guidelines for injured children at high risk for venous thromboembolism: A prospective observational study.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
